scholarly journals Non-steroidal anti-inflammatory drug use is determined by disease activity in axSpA and decreased by biologicals: a longitudinal analysis

2021 ◽  
Author(s):  
Elif Durak Ediboglu ◽  
Dilek Solmaz ◽  
Gökhan Kabadayı ◽  
Sercan Gücenmez ◽  
Haluk Cinaklı ◽  
...  
Keyword(s):  
Treatment Group ◽  
Disease Activity ◽  
Study Data ◽  
C Reactive Protein ◽  
Biologic Treatment ◽  
Inflammatory Drug ◽  
Reactive Protein ◽  
Anti Inflammatory ◽  
The Relationship

Abstract Objective To evaluate non-steroidal anti-inflammatory drug (NSAID) use and Assessment in Spondyloarthritis International Society (ASAS)-NSAID scores in patients with axial spondyloarhritis (axSpA) in a longitudinal study. Methods In total, 429 patients with axSpA (59% male; 63.6% with AS) were included in this study. Data about disease activity, C-reactive protein (CRP) levels, and NSAID use and dosage were collected at 0, 12, 24, and 52 weeks retrospectively. The relationship with NSAID use /NSAID scores and other factors was tested using generalized estimating equations (GEE). Results At baseline (0 weeks), 92.8% of patients started biologic disease-modifying anti-rheumatic drugs (bDMARDs) and 82.1% were conventionally treated with NSAIDs. At baseline, the proportion (p=0.03) and the median (IQR) ASAS-NSAID scores were higher in biologic treatment group [100 (50) vs 50 (83.4); p<0.001]. During follow-up, NSAID use and ASAS-NSAID scores decreased significantly in patients treated with bDMARDs (p<0.001) and the reduction remained stable throughout the follow-up However, neither NSAID use (p=0.06) nor ASAS-NSAID scores changed in conventionally treated patients (p=0.15). In bDMARD-treated patients, ASDAS-CRP and BASFI scores were independent determinants for NSAID use, and BASDAI and patient global assessment (PGA) were determinants for NSAID dosage. There was no independent significant predictor for ASAS-NSAID scores; PGA was the only significant predictor for NSAID use in the conventional treatment group. Conclusion Concurrent biologic treatment was associated with low NSAID intake in patients with axSpA, and NSAID use was determined mainly by disease activity and partly by function during bDMARD treatment.

scholarly journals A prospective follow-up study of the relationship between high-sensitivity C-reactive protein and primary liver cancer

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Sarah Tan Siyin ◽  
Tong Liu ◽  
Wenqiang Li ◽  
Nan Yao ◽  
Guoshuai Xu ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Regression Models ◽  
Primary Liver Cancer ◽  
High Sensitivity ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Hs Crp ◽  
The Relationship ◽  
New Onset

Abstract Background Competing risk method has not been used in a large-scale prospective study to investigate whether increased levels of high-sensitivity C-reactive protein (hs-CRP) elevate the risk of primary liver cancer (PLC). Our study aims to prospectively investigate the relationship between hs-CRP and new-onset PLC. Methods and results Ninety-five thousand seven hundred fifty-nine participants without the diagnosis of PLC, and who had their demographic characteristics and biochemical parameters recorded, were analyzed from the Kailuan Cohort study. Cox proportional hazards regression models and competing risk regression models were used to evaluate the hazard ratios (HRs) and 95% confidence intervals (95% CIs) of PLC. During a median follow-up of 11.07 years, 357 incidental PLC cases were identified over a total of 1,035,039 person-years. The multivariable HRs (95%CI) for the association of hs-CRP of 1–3 mg/L group and hs-CRP>3 mg/L with PLC were 1.07(0.82 ~ 1.38), 1.51(1.15 ~ 1.98) in a Cox proportional hazard regression analysis adjusted for other potential confounders. In the cause-specific hazard model, the multivariable HRs (95%CI) for the association of hs-CRP of 1–3 mg/L group and hs-CRP>3 mg/L with PLC were 1.06(0.81 ~ 1.40), 1.50(1.14 ~ 1.99). Similar results were also observed in the sub-distribution hazard function model with corresponding multivariate HRs (95%CI) of 1.05(0.80 ~ 1.40), 1.49(1.13 ~ 1.98) in hs-CRP of 1–3 mg/L group and hs-CRP>3 mg/L group, respectively. Conclusions This prospective study found a significant association of higher levels of hs-CRP with new-onset PLC. The main clinical implications would be an increased awareness of hs-CRP and its correlation to the risk of PLC. This study should be a steppingstone to further research on chronic inflammation and PLC. Trial registration Registration number:ChiCTR–TNRC–11001489.

scholarly journals The relationship between anti-C-reactive protein and disease activity in patients with systemic lupus erythematosus

2018 ◽  
Vol 33 (4) ◽  
pp. 823-828 ◽  
Author(s):  
Chang-Nam Son ◽  
Tae-Han Lee ◽  
Ji-Hye Bang ◽  
Hye-Jin Jeong ◽  
Jin-Nyeong Chae ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
C Reactive Protein ◽  
Systemic Lupus ◽  
Reactive Protein ◽  
The Relationship

The prognostic value of high-sensitivity C-reactive protein blood level after coronary stenting for the development of stent restenosis

Kardiologiia ◽  
2020 ◽  
Vol 60 (7) ◽  
pp. 64-71
Author(s):  
A. Yu. Filatova ◽  
G. V. Shlevkova ◽  
A. V. Potekhina ◽  
A. K. Osokina ◽  
E. A. Noeva ◽  
...  
Keyword(s):  
Roc Curve ◽  
Roc Analysis ◽  
High Sensitivity ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Stent Restenosis ◽  
Neointimal Proliferation ◽  
Exertional Angina ◽  
The Relationship

Aim      To analyze the relationship between serum concentrations of high-sensitivity C-reactive protein (hsCRP) in dynamics and development of restenosis at 12 months following elective coronary stent placement (CSP).Material and methods  The key role in atherogenesis, neointimal proliferation and restenosis belongs to inflammation. This study included 91 patients (median age, 60 [56; 66] years) with stable exertional angina after an elective CSP using second-generation stents. Follow-up coronarography was performed for 60 patients at 12 months. Concentration of hsCRP was measured immediately prior to CSP and at 1, 3, 6, and 12 months after CSP. Restenosis of the stented segment (50% or more narrowing of the stented segment or a 5-mm vessel segment proximally or distally adjacent to the stented segment) was observed in 8 patients.Results According to results of the ROC analysis, the increase in hsCRP concentration >0.9 mg/l (>25%) at one month after CSP had the highest predictive significance with respect of restenosis (area under the ROC curve, 0.89 at 95 % confidence interval (CI) from 0.79 to 0.99; sensitivity, 87.5 %; specificity, 82.8 %; р=0.0005), which was superior to the absolute value of hsCRP concentration >3.0 mg/l (area under the ROC curve, 0.82 at 95 % CI from 0.68 to 0.96; р=0.0007).Conclusion      Increased concentration of hsCRP ≥0.9 mg /l (≥25 %) at a month after CSP was associated with restenosis of the coronary artery stented segment.

Osteopontin in antineutrophil cytoplasmic autoantibody-associated vasculitis: relation to disease activity, organ manifestation and immunosuppressive therapy

2010 ◽  
Vol 69 (6) ◽  
pp. 1169-1171 ◽  
Author(s):  
Johan Lorenzen ◽  
Svjetlana Lovric ◽  
Robert Krämer ◽  
Hermann Haller ◽  
Marion Haubitz
Keyword(s):  
Disease Activity ◽  
Immunosuppressive Therapy ◽  
Plasma Levels ◽  
Filtration Rate ◽  
Inflammatory Process ◽  
C Reactive Protein ◽  
Birmingham Vasculitis Activity Score ◽  
Reactive Protein ◽  
Antineutrophil Cytoplasmic Autoantibody

BackgroundOsteopontin is a pleiotropic cytokine involved in the recruitment and retention of neutrophils to sites of inflammation, which are the primary targets cells in antineutrophil cytoplasmic autoantibody-associated vasculitis (AAV). Osteopontin may play a role in the pathogenesis of AAV.Methods24 patients with systemic AAV and six patients with limited granulomatous disease were included. 19 patients were followed up at 6 and 12 months after the initiation of immunosuppressive therapy. 21 matched healthy volunteers and 20 body mass index and glomerular filtration rate-matched patients with IgA nephropathy were included as controls. Plasma levels of osteopontin were measured by ELISA. Disease activity was gauged by the Birmingham vasculitis activity score (BVAS) and C-reactive protein (CRP).ResultsOsteopontin levels are elevated compared with controls (healthy p<0.001; IgA p<0.001).Osteopontin levels decrease significantly during follow-up (p=0.02). Osteopontin levels correlate with disease activity (BVAS r=0.93; CRP r=0.73; all p<0.001) as well as erythrocyturia (r=0.7, p<0.001) and proteinuria (r=0.54, p=0.007).ConclusionsActive AAV is characterised by increased plasma levels of osteopontin, which decrease dramatically with successful therapy. Osteopontin may mediate the inflammatory process in AAV through the recruitment of neutrophils.

scholarly journals Predictive factors related to the progression of periodontal disease in patients with early rheumatoid arthritis: a cohort study

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Ana María Heredia-P ◽  
Gloria Inés Lafaurie ◽  
Wilson Bautista-Molano ◽  
Tamy Goretty Trujillo ◽  
Philippe Chalem-Choueka ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Periodontal Disease ◽  
Disease Activity ◽  
Early Rheumatoid Arthritis ◽  
Predictive Factors ◽  
Related Protein ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Generalised Linear Mixed Model

Abstract Background Rheumatoid arthritis (RA) and periodontal disease are inter-related conditions. However, factors predictive of periodontal disease progression in patients with early rheumatoid arthritis (eRA) are lacking. The aim of this study was to identify factors associated with the progression of clinical attachment loss (CAL) in interproximal dental sites of eRA patients. Methods Twenty-eight eRA patients were evaluated for the progression of CAL at 280 interproximal dental sites at 1 year of follow-up. Markers of RA activity (rheumatoid factor, erythrocyte sedimentation rate, and C-reactive protein), a marker of bone resorption (Dickkopf-related protein 1), Disease Activity Score 28 and Simple Disease Activity Index were included as potential systemic predictive factors. Plaque index, gingival index, pocket depth, clinical attachment level and Dickkopf-related protein 1 in crevicular fluid at baseline were included as potential local predictive factors. Data were analysed in a hierarchical structure using generalised linear mixed models for progression at each site (> 2 mm) during follow-up. Results C-reactive protein level was the most important predictive systemic factor for the progression of CAL. The mean CAL and a high degree of gingival inflammation in interproximal sites at baseline were important predictive local factors (p <  0.0001). Patients who received combined treatment with disease-modifying antirheumatic drugs and corticosteroids exhibited less CAL (p <  0.0001). The predictive value of the generalised linear mixed model for progression was 85%. Conclusions Systemic factors, including RA disease activity and baseline periodontal condition, were associated with periodontal progression. Pharmacological treatment may affect periodontal progression in patients with early RA.

Sign in / Sign up

Export Citation Format

Share Document